Polymorphism of genes is factor efficiency anti ulcer pharmacotherapy
Abstract
AbstractPeptic ulcer disease is one of the variants of the typological response of the body when exogenous factors of the internal environment interact (type of the nervous system, endocrine system, psycho emotional characteristics, metabolism, biochemical reactions, and cytokine profile) with external exogenous factors. This pathology is one of the most common diseases of internal organs, and among the adult population it occurs in 7–12% of cases [1; 2; 3]. Type II stomach ulcers (Johnson H. D., 1965) or combined stomach and duodenal ulcers account for about 25% of the structure of gastric ulcers [7] According to modern research data, up to 10% of residents of Europe, the USA and Russia suffer from this disease (Ivashkin V.T., Minushkin O.N., 2015). In Uzbekistan, about 14% of people develop stomach ulcers; this disease is most common in men. (Https.//nuz.uz Jun 5, 2018) This review article also contains information on the significant effects of gene polymorphisms encoding biotransformation enzymes of drugs on the efficacy and safety of antiulcer pharmacotherapy. Determination of the polymorphism of the CYP3A5 gene makes it possible to initially determine the tactics of treatment with proton pump inhibitors in patients with peptic ulcer disease.